CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Grant or award General Counsel acquired 10,708 shares (grant or award)
- 4 Grant or award President and CEO acquired 30,339 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market sale Director sold 3,460 shares at $2.46 ($8,512)
- 4 Grant or award Head of Regulatory acquired 15,525 shares (grant or award)
- 4 Grant or award General Counsel acquired 22,000 shares (grant or award)
- 4 Grant or award VP, Clinical Trial Operations acquired 29,000 shares (grant or award)
- 4 Grant or award VP, Pharmaceutical Development acquired 29,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 41,650 shares (grant or award)
- 4 Grant or award President and CEO acquired 134,500 shares (grant or award)
- 4 Open-market sale President and CEO sold 14,315 shares at $2.34 ($33,497)
- 4 Open-market sale Chief Financial Officer sold 2,103 shares at $2.34 ($4,921)
- 4 Open-market sale Head of Regulatory sold 2,510 shares at $2.34 ($5,873)
- 4 Open-market sale VP, Pharmaceutical Development sold 6,300 shares at $2.34 ($14,742)
- 4 Derivatives Options or other derivatives
Page 4 of 10 · 190 filings